Bill Commons

MD HB 417

died on adjournment

Criminal Law - Schedule III Controlled Dangerous Substances - Medetomidine and Xylazine

Maryland · 2026 Regular Session · lower

Follow this bill’s action updates (Atom)

Subscribe in a feed reader. The feed covers recorded actions from the last 30 days; Bill Commons may record an action after it happened at the legislature.

Quick answers

Did MD HB 417 pass?

No. MD HB 417 died when the 2026 Regular Session adjourned without final action on it. Bills that die this way are sometimes reintroduced in a later session. Latest recorded action (2026-04-13): Motion Special Order until Next Session (Senator Love) Adopted

What is MD HB 417 about?

MD HB 417 is a bill in the 2026 Regular Session titled “Criminal Law - Schedule III Controlled Dangerous Substances - Medetomidine and Xylazine”.

Who sponsors MD HB 417?

Woorman, White Holland, Taveras and 18 others are the primary sponsors of MD HB 417.

Introduced
—
Latest action
2026-04-13 — Motion Special Order until Next Session (Senator Love) Adopted
Bill type
bill
Last updated
—

Sponsors

  • Woormanprimary
  • White Hollandprimary
  • Taverasprimary
  • Szeligaprimary
  • Rossprimary
  • Rosenbergprimary
  • Reillyprimary
  • M. Morganprimary
  • Martinezprimary
  • Lopezprimary
  • Kipkeprimary
  • Kaufmanprimary
  • S. Johnsonprimary
  • Hutchinsonprimary
  • Hillprimary
  • Guzzoneprimary
  • Cullisonprimary
  • Bagnallprimary
  • Alstonprimary
  • Kerrprimary
  • Pippyprimary

Committees

Not provided by source.

Action timeline

Newest first

  1. 2026-04-13

    Motion Special Order until Next Session (Senator Love) Adopted

  2. 2026-04-13

    Favorable

    committee-passage-favorable

  3. 2026-04-13

    Favorable Report by Finance

    committee-passage-favorable

  4. 2026-03-05

    Referred Finance

    referral-committee

  5. 2026-03-04

    Third Reading Passed

    passage

  6. 2026-03-03

    Second Reading Passed with Amendments

  7. 2026-03-03

    Favorable with Amendments {

    committee-passage-favorable

  8. 2026-03-03

    Favorable with Amendments Report by Health

    committee-passage-favorable

  9. 2026-02-10

    Hearing 2/10 at 2:30 p.m.

  10. 2026-02-10

    Hearing canceled

  11. 2026-01-22

    Hearing 2/10 at 2:00 p.m.

  12. 2026-01-22

    First Reading Health

    referral-committee

Versions

  • Third - Criminal Law - Schedule III Controlled Dangerous Substances - Medetomidine and XylazineCompare
  • First - Public Health - Medetomidine and Xylazine Consumer Protection ActCompare
  • (document, no version)Compare

Documents

Votes

  • On Third Reading

    2026-02-23 · pass · 127-0

    Member-level votes (141)
    • Speaker: yes
    • Crutchfield: yes
    • Jacobs: yes
    • Nkongolo: yes
    • Smith: yes
    • Acevero: yes
    • Cullison: yes
    • Johnson, A.: yes
    • Odom: yes
    • Solomon: yes
    • Adams: yes
    • Davis: yes
    • Johnson, S.: yes
    • Palakovich Carr: yes
    • Spiegel: yes
    • Addison: yes
    • Ebersole: yes
    • Jones, D.: yes
    • Pasteur: yes
    • Stein: yes
    • Allen: yes
    • Edelson: yes
    • Kaiser: yes
    • Patterson: yes
    • Stewart: yes
    • Amprey: yes
    • Embry: yes
    • Kaufman: yes
    • Phillips: yes
    • Stinnett: yes
    • Anderson: yes
    • Fair: yes
    • Kerr: yes
    • Pippy: yes
    • Stonko: yes
    • Arentz: yes
    • Feldmark: yes
    • Kipke: yes
    • Pruski: yes
    • Szeliga: yes
    • Arikan: yes
    • Fennell: yes
    • Korman: yes
    • Qi: yes
    • Taveras: yes
    • Bagnall: yes
    • Fisher: yes
    • Lehman: yes
    • Queen: yes
    • Taylor: yes
    • Baker: yes
    • Foley: yes
    • Lewis: yes
    • Reilly: yes
    • Terrasa: yes
    • Barnes: yes
    • Forbes: yes
    • Long, R.: yes
    • Roberson: yes
    • Toles: yes
    • Bartlett: yes
    • Fraser-Hidalgo: yes
    • Lopez: yes
    • Roberts: yes
    • Tomlinson: yes
    • Beauchamp: yes
    • Ghrist: yes
    • Mangione: yes
    • Rogers: yes
    • Turner: yes
    • Behler: yes
    • Griffith: yes
    • Martinez: yes
    • Rose: yes
    • Valderrama: yes
    • Bhandari: yes
    • Guyton: yes
    • McCaskill: yes
    • Rosenberg: yes
    • Valentine: yes
    • Boyce: yes
    • Guzzone: yes
    • McComas: yes
    • Ross: yes
    • Watson: yes
    • Buckel: yes
    • Harrison: yes
    • Metzgar: yes
    • Ruff: yes
    • Wells: yes
    • Cardin: yes
    • Hartman: yes
    • Miller: yes
    • Ruth: yes
    • White Holland: yes
    • Chang: yes
    • Hill: yes
    • Mireku-North: yes
    • Sample-Hughes: yes
    • Wilkins: yes
    • Charkoudian: yes
    • Hinebaugh: yes
    • Moon: yes
    • Schindler: yes
    • Wims: yes
    • Chisholm: yes
    • Holmes: yes
    • Moreno: yes
    • Schmidt: yes
    • Wolek: yes
    • Ciliberti: yes
    • Hornberger: yes
    • Morgan, M.: yes
    • Shetty: yes
    • Woorman: yes
    • Clippinger: yes
    • Howard: yes
    • Morgan, T.: yes
    • Simmons: yes
    • Wu: yes
    • Coley: yes
    • Hutchinson: yes
    • Nawrocki: yes
    • Simpson: yes
    • Ziegler: yes
    • Conaway: yes
    • Ivey: yes
    • Boafo: not voting
    • Bouchat: not voting
    • Wilson: not voting
    • Woods: not voting
    • Young: not voting
    • Alston: absent
    • Grammer: absent
    • Jones, A.: absent
    • Vogel: absent
    • Wivell: absent
    • Crosby: absent
    • Healey: absent
    • Long, J.: absent
    • Williams: absent

Related bills

  • Prior session: HB 1109not in this corpus
  • Companion bill: SB 435

Official source

Attribution

Data from openstates_bulk_csv, retrieved 2026-07-24T05:23:32.621655Z

Inspect retained evidence for changes recorded after evidence tracking began:

Session-wide evidence can include changes to other bills:

Use this data

Every field on this page is available from the free public API — no key or licence required. Fetch this bill as JSON: GET /api/v1/bills?jurisdiction=MD&identifier=HB 417. See the API docs or the MCP server for AI assistants.

Known limitations

  • Sponsor party and chamber affiliation are not yet captured by this API.
  • Committee referrals are not yet captured.

See the methodology page for data sources and limitations.